Table 2.
The observed and predicted 5-year OS of the MRI-based radiomics signature and NRI-M in patients with all-stages and early-stage ENKTCL.
| Risk group | No. (%) | Observed 5-year OS (%) |
P | Predicted 5-year OS (%) |
|
|---|---|---|---|---|---|
| All Stages (n = 176) | |||||
| MRI radiomics signature | 0.002 | ||||
| Type I (Favorable) | 65 (36.9) | 87.2 | 87.8 | ||
| Type II (Unfavorable) | 111 (63.1) | 67.3 | 66.7 | ||
| NRI-M | < 0.001 | ||||
| Low-risk (0–1) | 53 (30.1) | 90.5 | 90.9 | ||
| Intermediate-low-risk (2) | 37 (21.0) | 80.8 | 83.5 | ||
| Intermediate-high-risk (3) | 47 (26.7) | 69.6 | 70.9 | ||
| High-risk (4) | 28 (15.9) | 63.4 | 52.0 | ||
| Very high-risk (≥ 5) | 11 (6.3) | 22.7 | 28.8 | ||
| Stage I–II (n = 166) | |||||
| MRI radiomics signature | 0.004 | ||||
| Type I (Favorable) | 63 (38.0) | 88.8 | 88.9 | ||
| Type II (Unfavorable) | 103 (62.0) | 69.2 | 69.0 | ||
| NRI-M | < 0.001 | ||||
| Low-risk (0–1) | 53 (31.9) | 90.5 | 90.4 | ||
| Intermediate-low-risk (2) | 37 (22.3) | 80.8 | 82.9 | ||
| Intermediate-high-risk (3) | 45 (27.1) | 71.5 | 70.8 | ||
| High-risk (≥ 4) | 31 (18.7) | 54.8 | 52.8 |
Abbreviations: OS overall survival, MRI magnetic resonance imaging, NRI nomogram-revised risk index, NRI-M MRI radiomics-based NRI, ENKTCL extranodal nasal-type NK/T-cell lymphoma